Last reviewed · How we verify
Tafamidis free acid tablet
At a glance
| Generic name | Tafamidis free acid tablet |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fed Conditions (PHASE1)
- A Study to Compare Two Forms of Study Medicine Tafamidis in the Blood in Healthy Adults (PHASE1)
- A Study to Learn How Different Forms of Study Medicine Tafamidis Are Taken Up Into The Blood in Healthy Adults (PHASE1)
- A Study Comparing Two Forms of Tafamidis Without Food and the Amount of Tafamidis in the Blood With Food (PHASE1)
- A Study to Compare Two Tablet Forms of Tafamidis in Healthy Participants (PHASE1)
- A Study to Determine the Bioequivalence of Two Doses of Tafamidis (PHASE1)
- A Study Comparing Amounts of Tafamidis In The Blood Without Food (PHASE1)
- A Study Comparing The Amounts of Tafamidis In The Blood With Or Without Food (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tafamidis free acid tablet CI brief — competitive landscape report
- Tafamidis free acid tablet updates RSS · CI watch RSS
- Pfizer portfolio CI